

WHAT IS CLAIMED IS:

1. A method of treating or preventing a psychiatric disorder in a subject, the method comprising administering a Cox-2 inhibitor to the subject.
2. The method as set forth in claim 1, wherein the Cox-2 inhibitor is administered to the subject in combination with an antidepressant agent.
3. The method as set forth in claim 1, wherein the subject is in need of the prevention or treatment of a psychiatric disorder or a psychiatric disorder-related symptom.
4. The method as set forth in claim 1, wherein the Cox-2 inhibitor comprises at least one compound that is selected from the group consisting of acetaminophen, acetylsalicylic acid, alclofenac, alminoprofen, azapropazone, benorylate, benoxaprofen, bucloxic acid, carprofen, choline magnesium trisalicylate, clidanac, clopinac, dapsone, diclofenac, diflunisal, droxicam, etodolac, fenoprofen, fenbufen, fenclofenec, fentiazac, floctafenine, flufenisal, flurbiprofen, (r)-flurbiprofen, (s)-flurbiprofen, furofenac, feprazone, flufenamic acid, fluprofen, ibufenac, ibuprofen, indometacin, indomethacin, indoprofen, isoxepac, isoxicam, ketoprofen, ketorolac, miroprofen, piroxicam, meloxicam, mefenamic, mefenamic acid, meclofenamic acid, meclofen, nabumetone, naproxen, niflumic acid, oxaprozin, oxipinac, oxyphenbutazone, phenylbutazone, podophyllotoxin derivatives, proglumetacin, pirofen, piroprofen, prapoprofen, salicylic acid, salicylate, sudoxicam, suprofen, sulindac, tenoxicam, tiaprofenic acid, tiopinac, tioxaprofen, tolafenamic acid, tolmetin, zidometacin, zomepirac, 2-fluoro- α -methyl[1,1'-biphenyl]-4-acetic acid, 4-(nitrooxy)butyl ester, and mixtures thereof.

5. The method as set forth in claim 1, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, meloxicam, rofecoxib, lumiracoxib, etoricoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, SD-8381, prodrugs of any such compounds, and mixtures thereof.

6. The method as set forth in claim 5, wherein the Cox-2 selective inhibitor comprises a tricyclic Cox-2 selective inhibitor selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, rofecoxib, lumiracoxib, prodrugs of any such compounds, and mixtures thereof.

7. The method as set forth in claim 5, wherein the Cox-2 selective inhibitor comprises a chromene Cox-2 selective inhibitor selected from the group consisting of
6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid,
7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,

7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid,
6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,

6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-[[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[[N-(2-phenylethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid,
6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-formyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6-(difluoromethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-7-methyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,

(S)-6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6,8-dichloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
 5,6-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 2,6-bis(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 5,6,7-trichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 6,7,8-trichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 6-iodo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6-bromo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6-chloro-7-methyl-2-(trifluoromethyl)-2H-1-benzothiopyran-3-carboxylic
 acid,
 6,8-dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid,
 (S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-
 carboxylic acid,
 (2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
 (2S)-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
 (2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-
 carboxylic acid,
 (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 (2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic
 acid, and mixtures thereof.

8. The method as set forth in claim 2, wherein the antidepressant agent is selected from the group consisting of sertraline, citalopram, escitalopram oxalate, fluvoxamine, paroxetine, fluoxetine, amitriptyline, desipramine, imipramine, maprotiline, reboxetine, nortriptyline, amineptine, zimelidine, venlafaxine, mirtazapine, milnacipran, phenelzine, tranylcypromine, nefazodone, trazodone, bupropion, clomipramine, tandospirone, isocarboxazid, lithium carbonate, lithium citrate, doxepin, amoxapine, moclobemide, trimipramine, selegiline, protriptyline, viloxazine, alprazolam, pargyline, dextroamphetamine,

methylphenidate, diazepam, buspirone, tianeptine, binodaline,
 caroxazone, dimethazan, fencamine, indalpine, indeloxazine
 hydrochloride, nefopam, nomifensine, oxitriptan, oxypertine, thiazesim,
 benmoxine, iproclozide, iproniazid, L-tryptophan, nialamide, octamoxin,
 toloxatone, cotinine, rolicyprine, rolipram, metralindole, mianserin,
 adinazolam, amitriptylinoxide, butriptyline, dibenzepin, dimetacrine,
 dothiepin, fluacizine, imipramine N-oxide, iprindole, lofepramine,
 melitracen, metapramine, noxiptilin, opipramol, pizotyline, propizepine,
 quinupramine, tofenacin, adrafinil, benactyzine, butacetin, dioxadrol,
 duloxetine, etoperidone, febarbamate, femoxetine, fenpentadiol,
 hematoporphyrin, hypericin, levophacetoperane, medifoxamine,
 minaprine, oxaflozane, piberaline, prolintane, pyrisuccideanol, ritanserin,
 roxindole, rubidium chloride, sulpiride, thozalinone, amantadine,
 amiflamine, amisulpride, amphetamine, aprepitant, aripiprazole,
 atomoxetine, befloxatone, brofaromine, bromocriptine, buprenorphine,
 cericlamine, ciclazindol, cimoxatone, clorgyline, clovoxamine, dapoxetine,
 demexiptiline, dexmethylphenidate, etryptamine, fengabine, flerobuterol,
 flesinoxan, flibanserin, fluparoxan, gepirone, idazoxan, igmesine,
 incazane, ipsapirone, isradipine, levodopa, lamotrigine, levoprotiline,
 liothyronine, litoxetine, mazindol, mebanazine, mefexamide, memantine,
 mifepristone, modafinil, nemifitide, nisoxetine, nitroxazepine, olanzapine,
 oxaprotiline, oxycodone, ziprasidone, pemoline, pergolide,
 phenoxypropazine, phentermine, pindolol, piribedil, pirlindole or pyrazidol,
 pramipexole, pregabalin, pyrovalerone, risperidone, ropinirole,
 sibutramine, talipexole, tetrindole, thyroxine, tolcapone, vilazodone,
 viqualine, yohimbine, asenapine, 1-pyrimidinylpiperazine, 6-hydroxy-
 buspirone, and mixtures thereof.

9. The method as set forth in claim 1, wherein the subject
 suffers from or is predisposed to one or more psychiatric disorders
 selected from the group consisting of depression, manic depression,
 anxiety disorder, anxious depression, panic disorder, attention deficit

disorder, attention deficit/hyperactivity disorder, dysthymic disorder, cyclothymic disorder, posttraumatic stress disorder, obsessive compulsive disorder, premenstrual dysphonic disorder, schizophrenia, autism, agoraphobia, specific phobias, social phobia, acute stress disorder, and dissociative disorders.

10. The method as set forth in claim 1, wherein the subject suffers from or is predisposed to depression.

11. A pharmaceutical composition for preventing or treating psychiatric disorders in a subject, the composition comprising a Cox-2 inhibitor and an antidepressant agent.

12. The pharmaceutical composition as set forth in claim 11, wherein the Cox-2 inhibitor comprises at least one compound that is selected from the group consisting of acetaminophen, acetylsalicylic acid, alclofenac, alminoprofen, azapropazone, benorylate, benoxaprofen, bucloxic acid, carprofen, choline magnesium trisalicylate, clidanac, clopinac, dapsone, diclofenac, diflunisal, droxicam, etodolac, fenoprofen, fenbufen, fenclofenec, fentiazac, floctafenine, flufenisal, flurbiprofen, (r)-flurbiprofen, (s)-flurbiprofen, furofenac, feprazone, flufenamic acid, fluprofen, ibufenac, ibuprofen, indometacin, indomethacin, indoprofen, isoxepac, isoxicam, ketoprofen, ketorolac, miroprofen, piroxicam, meloxicam, mefenamic, mefenamic acid, meclofenamic acid, meclofen, nabumetone, naproxen, niflumic acid, oxaprozin, oxipinac, oxyphenbutazone, phenylbutazone, podophyllotoxin derivatives, proglumetacin, pirofen, piroprofen, prapoprofen, salicylic acid, salicylate, sudoxicam, suprofen, sulindac, tenoxicam, tiaprofenic acid, tiopinac, tioxaprofen, tolfenamic acid, tolmetin, zidometacin, zomepirac, 2-fluoro-*a*-methyl[1,1'-biphenyl]-4-acetic acid, 4-(nitrooxy)butyl ester, and mixtures thereof.

13. The pharmaceutical composition as set forth in claim 11, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, meloxicam, rofecoxib, lumiracoxib, etoricoxib, RS 57067, T-614, BMS-347070, JTE-522, S-2474, SVT-2016, CT-3, ABT-963, SC-58125, nimesulide, flosulide, NS-398, L-745337, RWJ-63556, L-784512, darbufelone, CS-502, LAS-34475, LAS-34555, S-33516, SD-8381, prodrugs of any such compound, and mixtures thereof.

14. The pharmaceutical composition as set forth in claim 13, wherein the Cox-2 selective inhibitor comprises a tricyclic Cox-2 selective inhibitor selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib, etoricoxib, rofecoxib, lumiracoxib, prodrugs of any such compound, and mixtures thereof.

15. The pharmaceutical composition as set forth in claim 13, wherein the Cox-2 selective inhibitor comprises a chromene Cox-2 selective inhibitor selected from the group consisting of 6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 6-chloro-7-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 6-chloro-8-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 2-trifluoromethyl-3H-naphthopyran-3-carboxylic acid, 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 6-bromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 5,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid, 8-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,

7,8-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-bis(dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
acid,
7-(1-methylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-8-ethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-phenyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
2-trifluoromethyl-3H-naptho[2,1-b]pyran-3-carboxylic acid,
6-chloro-8-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-bromo-8-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-6-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-6-methyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-bromo-5-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-8-fluoro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-bromo-8-methoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
6-[(dimethylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
6-[(methylamino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
acid,
6-[(4-morpholino)sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
acid,
6-[(1,1-dimethylethyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
6-[(2-methylpropyl)aminosulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,

6-methylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-6-[[[(phenylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-
benzopyran-3-carboxylic acid,
6-phenylacetyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dibromo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
8-chloro-5,6-dimethyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-(S)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-benzylsulfonyl-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-[[N-(2-furylmethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
6-[[N-(2-phenylethyl)amino]sulfonyl]-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
6-iodo-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
7-(1,1-dimethylethyl)-2-pentafluoroethyl-2H-1-benzopyran-3-carboxylic
acid,
6-chloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid.
6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6-chloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-
carboxylic acid,
(S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-
carboxylic acid,
6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6-trifluoromethoxy-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic
acid,
6-formyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6-(difluoromethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6,8-dichloro-7-methyl-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic
acid,
6,8-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
(S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,

(S)-6-chloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6,8-dichloro-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 7-(1,1-dimethylethyl)-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
 6,7-dichloro-2-trifluoromethyl-2H-1-benzopyran-3-carboxylic acid,
 5,6-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 2,6-bis(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 5,6,7-trichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 6,7,8-trichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 6-iodo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6-bromo-1,2-dihydro-2-(trifluoromethyl)-3-quinolinecarboxylic acid,
 6-chloro-7-methyl-2-(trifluoromethyl)-2H-1-benzothiopyran-3-carboxylic
 acid,
 6,8-dichloro-2-trifluoromethyl-2H-1-benzothiopyran-3-carboxylic acid,
 (S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-
 carboxylic acid,
 (2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
 (2S)-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
 (2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-
 carboxylic acid,
 (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
 (2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic
 acid, and mixtures thereof.

16. The pharmaceutical composition as set forth in claim 11,
 wherein the antidepressant agent is selected from the group consisting of
 sertraline, citalopram, escitalopram oxalate, fluvoxamine, paroxetine,
 fluoxetine, amitriptyline, desipramine, imipramine, maprotiline, reboxetine,
 nortriptyline, amineptine, zimelidine, venlafaxine, mirtazapine, milnacipran,
 phenelzine, tranylcypromine, nefazodone, trazodone, bupropion,
 clomipramine, tandospirone, isocarboxazid, lithium carbonate, lithium
 citrate, doxepin, amoxapine, moclobemide, trimipramine, selegiline,
 protriptyline, viloxazine, alprazolam, pargyline, dextroamphetamine,

methlyphenidate, diazepam, buspirone, tianeptine, binodaline, caroxazone, dimethazan, fencamine, indalpine, indeloxazine hydrochloride, nefopam, nomifensine, oxitriptan, oxypertine, thiazesim, benmoxine, iproclozide, iproniazid, L-tryptophan, nialamide, octamoxin, toloxatone, cotinine, rolicyprine, rolipram, metralindole, mianserin, adinazolam, amitriptylinoxide, butriptyline, dibenzepin, dimetacrine, dothiepin, fluacizine, imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, noxiptilin, opipramol, pizotyline, propizepine, quinupramine, tofenacin, adrafinil, benactyzine, butacetin, dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fempentadiol, hematoporphyrin, hypericin, levophacetoperane, medifoxamine, minaprine, oxaflozane, piberaline, prolintane, pyrisuccideanol, ritanserin, roxindole, rubdium chloride, sulpiride, thozalinone, amantadine, amiflamine, amisulpride, amphetamine, aprepitant, aripiprazole, atomoxetine, befloxatone, brofaromine, bromocriptine, buprenorphine, cericlamine, ciclazindol, cimoxatone, clorgyline, clovoxamine, dapoxetine, demexiptiline, dexmethlyphenidate, etryptamine, fengabine, flerobuterol, flesinoxan, flibanserin, fluparoxan, gepirone, idazoxan, igmesine, incazane, ipsapirone, isradipine, levodopa, lamotrigine, levoprotiline, liothyronine, litoxetine, mazindol, mebanazine, mefexamide, memantine, mifepristone, modafinil, nemifitide, nisooxetine, nitroxazepine, olanzapine, oxaprotiline, oxycodone, ziprasidone, pemoline, pergolide, phenoxypropazine, phentermine, pindolol, piribedil, pirlindole or pyrazidol, pramipexole, pregabalin, pyrovalerone, risperidone, ropinirole, sibutramine, talipexole, tetrindole, thyroxine, tolcapone, vilazodone, viqualine, yohimbine, asenapine, 1-pyrimidinylpiperazine, 6-hydroxy-buspirone, and mixtures thereof.

17. The pharmaceutical composition as set forth in claim 11, wherein the Cox-2 inhibitor comprises celecoxib and the antidepressant agent comprises sertraline.

18. A kit for preventing or treating psychiatric disorders in a subject, the kit comprising one dosage form comprising a Cox-2 inhibitor and a second dosage form comprising an antidepressant agent.

19. The kit as set forth in claim 18, wherein the Cox-2 inhibitor comprises celecoxib and the antidepressant agent comprises sertraline.